This product is for research use only, not for human use. We do not sell to patients.
Size | Price | Stock |
---|---|---|
250mg | $1450 | In Stock |
500mg | $2300 | In Stock |
1g | $3450 | In Stock |
Cat #: V4904 CAS #: 192564-14-0 Purity ≥ 98%
Description: Oritavancin diphosphate (LY-333328; LY 333328; LY333328; trade name Orbactiv), the diphosphate of Oritavancin, is a semisynthetic lipoglycopeptide analog of vancomycin approved in 2014 by FDA as an antibiotic for the treatment of serious Gram-positive bacterial infections.
Publications Citing InvivoChem Products
Product Promise
- Physicochemical and Storage Information
- Protocol
- Related Biological Data
- Stock Solution Preparation
- Quality Control Documentation
Molecular Weight (MW) | 1989.09 |
---|---|
Molecular Formula | C86H103Cl3N10O34P2 |
CAS No. | 192564-14-0 |
Storage | -20℃ for 3 years in powder formr |
-80℃ for 2 years in solvent | |
SMILES Code | C[C@H]1[C@H](O)[C@@](C)(N)C[C@H](O[C@H]2[C@H]3C(N[C@H](C(O)=O)C4=CC(O)=CC(O)=C4C5=C(O)C=CC([C@@H](NC([C@H]6C7=CC(OC8=C(Cl)C=C2C=C8)=C(O[C@H]9[C@H](O[C@H]%10C[C@](C)(NCC%11=CC=C(C%12=CC=C(Cl)C=C%12)C=C%11)[C@@H](O)[C@H](C)O%10)[C@@H](O)[C@H](O)[C@@H](CO)O9)C(OC%13=C(Cl)C=C([C@@H](O)[C@@H](NC([C@H](NC)CC(C)C)=O)C(N[C@@H](CC(N)=O)C(N6)=O)=O)C=C%13)=C7)=O)C(N3)=O)=C5)=O)O1.O=P(O)(O)O.O=P(O)(O)O |
Synonyms | LY333328; Oritavancin; Oritavancin diphosphate; LY-333328; LY 333328 |
Solvent volume to be added | Mass (the weight of a compound) | |||
---|---|---|---|---|
Mother liquor concentration | 1mg | 5mg | 10mg | 20mg |
1mM | 0.5027 mL | 2.5137 mL | 5.0274 mL | 10.0548 mL |
5mM | 0.1005 mL | 0.5027 mL | 1.0055 mL | 2.0110 mL |
10mM | 0.0503 mL | 0.2514 mL | 0.5027 mL | 1.0055 mL |
20mM | 0.0251 mL | 0.1257 mL | 0.2514 mL | 0.5027 mL |
This equation is commonly abbreviated as: C1 V1 = C2 V2
- (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
- (2) Be sure to add the solvent(s) in order.